Welcome to our dedicated page for Pharmadrug news (Ticker: LMLLF), a resource for investors and traders seeking the latest updates and insights on Pharmadrug stock.
PharmaDrug Inc. (OTC Pink: LMLLF) generates news primarily around specialty pharmaceutical development, corporate strategy and financing activities. Company releases describe a focus on the research, development and commercialization of controlled-substances and natural medicines, including psychedelics and previously approved drugs, with particular emphasis on cepharanthine and its reformulated version PD-001 through majority-owned Sairiyo Therapeutics.
News updates frequently cover progress in the cepharanthine program, such as stability studies for PD-001 and regulatory milestones supporting first-in-human Phase 1 clinical studies in Australia for viral infectious diseases. These items provide context on how PharmaDrug is advancing its clinical pipeline and working with contract development and manufacturing organizations to prepare trial material.
Another recurring theme in PharmaDrug’s news flow is strategic and corporate development. The company has reported a strategic review process led by a special committee to evaluate its assets, research programs and capital structure. It has also announced decisions regarding its subsidiary SecureDose Synthetics Inc., including the decision to cease activities there and concentrate on therapeutic molecules and medical products.
Investors following LMLLF can also expect updates on PharmaDrug’s collaboration with Canurta Limited Partnership and Canurta Inc., including letters of intent, definitive agreements and tranche closings for PharmaDrug’s planned equity interest in Canurta. Financing-related news, such as the issuance or restructuring of secured convertible debentures and associated warrants, is another key category of announcements.
By reviewing this news feed, readers can monitor developments in PharmaDrug’s clinical programs, its work in natural and psychedelic medicines, its botanical therapeutics collaboration with Canurta and its ongoing capital structure and strategic review activities.
PharmaDrug Inc. (CSE: PHRX, OTC Pink: LMLLF) has initiated start-up activities for its first clinical study of PD-001, a patented enteric-coated cepharanthine formulation, as a potential treatment for viral infectious diseases. The Phase 1 clinical study, approved by the Australian Human Research Ethics Committee, will assess the bioavailability and pharmacokinetics of PD-001 compared to oral cepharanthine tablets in healthy volunteers.
The study will involve 15 volunteers and last up to 49 days. It aims to demonstrate that PD-001 can achieve better oral pharmacokinetics than generic cepharanthine tablets with similar or improved safety. Upon successful completion, Sairiyo Therapeutics (51% owned by PharmaDrug) plans to seek FDA acceptance for a Phase 2 clinical study in viral infectious diseases.
PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) has announced strategic plans to advance the clinical development of PD-001, its patented enteric-coated Cepharanthine formulation, for viral infectious diseases. Sairiyo Therapeutics Inc., 51% owned by PharmaDrug, received approval to initiate a first-in-human Phase 1 clinical study. This follows a $3.4 million contract from the Defense Threat Reduction Agency for the Ebola virus.
PD-001 aims to improve the bioavailability of Cepharanthine, a Japanese-approved drug with potential antiviral activity against various viruses, including coronavirus, HIV-1, and Zika. The new formulation addresses Cepharanthine's low solubility and bioavailability issues, potentially enabling oral administration and eliminating the need for frequent intravenous dosing.
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) has announced that an independent screening has identified cepharanthine's potential to bind to monkeypox (Mpox) proteins. The study, published in the Journal of Infection, showed that cepharanthine displayed significant binding affinities to all ten target proteins of Mpox, with high affinities to four specific proteins.
Sairiyo Therapeutics Inc., 51% owned by PharmaDrug, is developing a patented reformulated version of oral cepharanthine (PD-001) for potential treatment of Medical Countermeasures and cancer. The company has received approval to initiate a Phase 1 clinical study in Australia. PD-001 was previously awarded a $3.4 million contract from the Defense Threat Reduction Agency (DTRA) for the Ebola virus.
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) has announced that its 51%-owned subsidiary, Sairiyo Therapeutics, received approval on August 12, 2024, to initiate a Phase 1 clinical trial for PD-001, a patented reformulated enteric coated version of oral cepharanthine. The study, approved by the Australian Human Research Ethics Committee, will investigate PD-001 as a potential treatment for Medical Countermeasures and cancer.
PD-001 previously received a $3.4 million contract from the Defense Threat Reduction Agency (DTRA) for Ebola virus research. The Phase 1 trial will assess the bioavailability and pharmacokinetics of 15 mg and 30 mg capsules of PD-001 compared to 15 mg oral cepharanthine tablets in healthy volunteers. Upon completion, Sairiyo plans to submit an Investigational New Drug application to the FDA for Phase 2 and 3 trials in the United States.
PharmaDrug's subsidiary, SecureDose, has signed a Letter of Intent (LOI) with a Canadian licensed drug dealer to manufacture pharmaceutical grade cocaine. This LOI, signed on May 16, 2024, allows SecureDose to initiate technology transfer for its patented cocaine synthesis method, aiming for a full manufacturing and distribution agreement. The partnership marks a strategic step to produce commercial-scale cocaine batches for safe supply programs. PharmaDrug aims to contribute to harm reduction by offering a regulated, biosynthetic alternative to contaminated street drugs.
PharmaDrug's Sairiyo Therapeutics has filed a clinical trial application with the Australian Human Research Ethics Committee for a Phase 1 study of its patented reformulated cepharanthine (PD-001). This study will evaluate the bioavailability and pharmacokinetics of 30 mg and 60 mg enteric-coated capsules compared to 6 mg tablets in healthy volunteers. If approved in June 2024, this trial will be the first human test of PD-001, aimed at treating infectious diseases and oncology. Sairiyo's Australian subsidiary will sponsor the study. The initiative leverages Australia's drug development incentives, offering a 43.5% tax rebate. Successful completion may lead to FDA applications for further trials in the U.S.
PharmaDrug Inc. (CSE: PHRX) provides an update on its patent-pending biosynthetic cocaine manufacturing process, focusing on commercialization and safe supply programs. CEO Robert Steen outlines the strategic plan to accelerate commercialization, engage in global partnerships, and streamline regulatory processes. The company aims to deliver pharmaceutical-grade cocaine to meet increasing demand, with a focus on innovative production methods and market distribution for 2024.
PharmaDrug Inc. announces the appointment of Zalman Goldman to its board of directors, with a background in addiction and recovery, to advance the company's mission in drug research and commercialization. Concurrently, Nickolai Vassev resigns from the board. Mr. Goldman brings valuable experience to the company, receiving 500,000 stock options as part of his appointment.
PharmaDrug's Sairiyo Therapeutics has finished the clinical and regulatory package for a Phase 1 study of their reformulated cepharanthine in Australia. This patented drug, PD-001, aims to treat infectious diseases and oncology. Sairiyo will conduct the study in Australia to benefit from drug development incentives, planning to submit an Investigational New Drug application to the FDA afterward.
Summary not available.
FAQ
What is the current stock price of Pharmadrug (LMLLF)?
What is the market cap of Pharmadrug (LMLLF)?
